Sofosbuvir/velpatasvir - Gilead Sciences

Drug Profile

Sofosbuvir/velpatasvir - Gilead Sciences

Alternative Names: Epclusa; GS 5816/sofosbuvir; GS 7977/GS 5816; SOF/VEL; Sofosbuvir/GS 5816; Velpatasvir/sofosbuvir

Latest Information Update: 12 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gilead Sciences
  • Class Antivirals; Carbamates; Chromans; Imidazoles; Naphthols; Phenylacetates; Phosphoric acid esters; Pyrimidine nucleotides; Pyrrolidines; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 21 Sep 2017 Health Canada approves sofosbuvir/velpatasvir for expanded indication for treatment of Hepatitis C (in patients co-infected with HIV) in Canada
  • 19 Sep 2017 University Health Network, Toronto and Gilead Sciences initiates enrolment in a phase I trial for Hepatitis C in Canada (NCT03112044)
  • 13 Sep 2017 Gilead Sciences completes a phase III trial for Hepatitis C in Sweden and Russia (PO) (NCT02722837)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top